Compare Danaher Corporation (DHR) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Under Armour Inc Class A — how do they compare? Danaher Corporation trades at $219.22 (market cap $152.87B), while Under Armour Inc Class A trades at $4.77 (market cap $2.07B). The key difference: Danaher Corporation is far larger — about 73.9× Under Armour Inc Class A's market cap, and Danaher Corporation pays a 0.74% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Under Armour Inc Class A for 18 Days on average.
| DHR | UA | |
|---|---|---|
Market Cap | $152.87B | $2.07B |
Volume | 5,228,698 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $7.88 |
52-Week Low | $161.91 | $3.96 |
Typical Hold Time | 69 Days | 18 Days |
Enterprise Value | $175.08B | $3.05B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Under Armour (UA) trades at $4.75, up 1.06% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 EPS beat but faces revenue declines and negative profitability metrics, including a -9.99% net income margin. Cash flow remains negative at -$362M for 2025, while analyst consensus shows 40% buy ratings amid ongoing operational challenges.
Outlook remains cautious with revenue guidance cuts and competitive pressures. Investment opportunity exists if turnaround strategies succeed, but risks include sustained negative cash flow, weak consumer demand, and high debt levels. The stock's low P/S ratio of 0.41 offers value potential if management can stabilize operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
